v3.26.1
Collaboration, License, and Supply Agreements - Sanofi (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues $ 139,514 $ 666,655  
Current deferred revenue 88,772   $ 140,053
Noncurrent deferred revenue 359,273   $ 358,943
Capitalized contract cost, amortization 1,400    
Royalties | Sanofi      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues 3,521 0  
Sanofi      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments $ 350,000    
Proceeds development, tech transfer, launch, and sales milestone collaboration payment, term 20 years    
Sanofi | Selling, general, and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Capitalized contract cost, amortization $ 900 900  
Sanofi | Licensed COVID-19 products and royalty payments      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments 75,000    
Sanofi | Royalties      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues 3,500    
Sanofi | CIC Product-Related Development Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments 125,000    
Sanofi | CIC Product-Related Launch Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments 225,000    
Sanofi | First Four Adjuvant Products      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments 200,000    
Sanofi | Adjuvant Products Thereafter      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Development, tech transfer, launch, and sales milestone payments 210,000    
Sanofi | Transition Services      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total licensing, royalties, and other revenue 45,400 $ 40,300  
Deferred revenue 4,700    
Current deferred revenue 2,200    
Noncurrent deferred revenue 2,500    
Cumulative catch up adjustment 6,100    
Sanofi | Product and Service, Other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Capitalized contract cost, amortization $ 35,000